Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announced that Health Canada has granted the "Notice of Compliance" (NOC) for Ranopto (Ranibizumab), a biosimilar to Lucentis, for the treatment of several serious retinal diseasein Canada. Ranopto is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), the treatment of visual imprmement due to diabetic macular oedema (DME) or choroidal neovascularization (CNV), as well as treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO). FYB201/Ranopto® was developed by Bioeq, a Joint Venture between Formycon and Polpharma Biologics.

Mid 2021, Teva Pharmaceutical Industries Ltd. (Teva) entered into a strategic partnership for the exclusive commercialization of FYB201 in Canada, Europe and selected other countries. Commercial launch by Teva Canada Ltd. is expected to start in the first quarter of 2024.